PROHaleon
stock354.80p
+5.60 (+1.60%)
Price as of 13 Oct, 12:31 · Rate limit reached. Please try again in a minute.
Good Money Guide Pro Score
Attractive
Attractive investment profile
Technical Analysis
Short-Term Outlook
Neutral
2 bull · 2 bear · 1 neutral
Medium-Term Outlook
Bullish
3 bull · 1 bear · 0 neutral
Price above 50-day MA
Price below 200-day MA
Price above 12-day EMA
Price above 26-day EMA
Neutral momentum zone
MACD above signal line
Overbought — potential reversal down
Price near upper band — potential reversal
Volatility measure — informational only
Volume Indicators
On Balance Volume (OBV)
Volume Accumulation Distribution (VAD)
Market Statistics
Day Change
+5.60p
Exchange
LSE
Sector
Pharmaceuticals & biotechnology
FCA Net Short Position
Position date: 28 Sep 2026
The aggregated net short position reported to the FCA by all position holders with positions ≥ 0.2%.
Fundamentals
Rate limit reached. Please try again in a minute.
Analyst Forecast
Rate limit reached. Please try again in a minute.
Learn about Haleon
What is Haleon?
Haleon is a global consumer healthcare company that was spun off from GSK, focusing on over-the-counter medicines, vitamins, and oral health products. It manages well-known household brands such as Sensodyne, Panadol, and Advil. The company operates by leveraging its diverse portfolio of everyday wellness products to meet the daily needs of consumers worldwide.
Is Haleon a good investment?
Haleon offers a stable defensive profile with strong brand loyalty and consistent cash flow, which can be appealing during economic uncertainty. However, it faces challenges such as high debt levels from its separation and intense competition in the retail pharmacy market. Please remember that this information is for educational purposes only and does not constitute financial advice.
How do you invest in Haleon?
You can invest in Haleon by purchasing its shares through a regulated online stockbroker or trading platform that provides access to the London Stock Exchange. Alternatively, you can gain exposure to the broader healthcare sector by investing in ETFs that include Haleon as a constituent. Always check with your chosen provider to ensure they support trading in the relevant market.
Educational content generated by AI — not financial advice.
Time & Sales
No trades yet.
News & Sentiment
Rate limit reached. Please try again in a minute.
Community Discussion
No posts yet for HLN — be the first to start the discussion.
Point & Figure Analysis
OHLC
Signals
as of 06 Oct 2026Targets
Famous Investors Holding HLN
Ken Griffin
854.4K sh · 0.0% of portfolio
$7.97M
NEW
Ken Griffin
808.7K sh · 0.0% of portfolio
$7.55M
NEW
Ray Dalio
403.1K sh · 0.0% of portfolio
$3.76M
NEW
Ken Griffin
11.5K sh · 0.0% of portfolio
$107.3K
NEW
Source: SEC Form 13F, reporting period 30 Jun 2026. 45-day lag applies.